Blog

DrugPatentWatch provides competitive intelligence on small-molecule drugs and the 90,000 global patents covering them

Click the patents below for more details, or visit DrugPatentWatch.com for more options.

ZYVOX (linezolid)
Pharmacia And Upjohn
Patent number: 5,688,792
Expiration Date: May 18, 2015


SANDOSTATIN LAR (octreotide acetate)
Novartis
Patent number: 5,688,530
Expiration Date: May 18, 2015


RISPERDAL CONSTA (risperidone)
Janssen Pharms
Patent number: 5,688,801
Expiration Date: May 18, 2015


ASMANEX TWISTHALER (mometasone furoate)
Merck Sharp Dohme
Patent number: 5,687,710
Expiration Date: May 18, 2015


MACUGEN (pegaptanib sodium)
Valeant Pharms Llc
Patent number: 6,051,698
Expiration Date: May 19, 2015


LIVALO (pitavastatin calcium)
Kowa Co
Patent number: 5,753,675
Expiration Date: May 19, 2015


OCTREOSCAN (indium in-111 pentetreotide kit)
Mallinckrodt
Patent number: 5,753,627
Expiration Date: May 19, 2015


For more information try a free trial

DrugPatentWatch provides competitive intelligence on small-molecule drugs and the 90,000 global patents covering them

Click the patents below for more details, or visit DrugPatentWatch.com for more options.

SANDOSTATIN LAR (octreotide acetate)
Novartis
Patent number: 5,688,530
Expiration Date: May 18, 2015


RISPERDAL CONSTA (risperidone)
Janssen Pharms
Patent number: 5,688,801
Expiration Date: May 18, 2015


ASMANEX TWISTHALER (mometasone furoate)
Merck Sharp Dohme
Patent number: 5,687,710
Expiration Date: May 18, 2015


ZYVOX (linezolid)
Pharmacia And Upjohn
Patent number: 5,688,792
Expiration Date: May 18, 2015


MACUGEN (pegaptanib sodium)
Valeant Pharms Llc
Patent number: 6,051,698
Expiration Date: May 19, 2015


LIVALO (pitavastatin calcium)
Kowa Co
Patent number: 5,753,675
Expiration Date: May 19, 2015


OCTREOSCAN (indium in-111 pentetreotide kit)
Mallinckrodt
Patent number: 5,753,627
Expiration Date: May 19, 2015


For more information try a free trial

TechTransferWatch is a search engine and alert service for licenseable technologies from academic labs, foundations, and government.

Click the patents below for more details, or visit TechTransferWatch.com for more options.

Genotypic tumor progression classifier and predictor
Timothy Yeatman, Steven Alan Enkemann, Steven Eschrich, Timothy Yeatman, Steven Alan Enkemann, Steven Eschrich
University of South Florida
Patent number: 9,037,416
Issue Date: May 19, 2015


Method to develop high oleic acid soybeans using conventional soybean breeding techniques
Kristin Bilyeu, Grover Shannon, Jeong-Dong Lee, Anh Tung Pham, Kristin Bilyeu, Grover Shannon, Jeong-Dong Lee, Anh Tung Pham
University of Missouri
Patent number: 9,035,129
Issue Date: May 19, 2015


Antisense oligonucleotides for inducing exon skipping and methods of use thereof
University of Western Australia
Patent number: 9,035,040
Issue Date: May 19, 2015


Temperature sensitive conjugate compositions
Elliot L. Chaikof, Karlheinz Peter, Danijal Topcic, Carolyn A. Haller, Wookhyun Kim
Emory University
Patent number: 9,035,028
Issue Date: May 19, 2015


Cyclic CRF antagonist peptides
Jean E. F. Rivier
Salk Institute for Biological Studies
Patent number: 9,035,022
Issue Date: May 19, 2015


Acyl piperidine inhibitors of soluble epoxide hydrolase
University of California
Patent number: 9,034,903
Issue Date: May 19, 2015


miR-31 in duchenne muscular dystrophy therapy
Irene Bozzoni, Julie Martone, Davide Cacchiarelli, Tania Incitti
Università degli Studi di Roma, La Sapienza
Patent number: 9,034,838
Issue Date: May 19, 2015


Syndecan peptides and polypeptides as inhibitors of cancer
Wisconsin Alumni Research Foundation
Patent number: 9,034,828
Issue Date: May 19, 2015


Syndecan peptides and polypeptides as inhibitors of cancer
Wisconsin Alumni Research Foundation
Patent number: 9,034,827
Issue Date: May 19, 2015


Treatment of myocardial injury with humanin analogs
Radhika Muzumdar, David J. Lefer
Albert Einstein College of Medicine
Patent number: 9,034,825
Issue Date: May 19, 2015


sgp130/Fc dimers for treatment of inflammatory disease
Conaris Research Institute
Patent number: 9,034,817
Issue Date: May 19, 2015


CXCR4 antagonists for wound healing and re-epithelialization
Amnon Peled, Nobutaka Fujii
Kyoto University
Patent number: 9,034,814
Issue Date: May 19, 2015


Methods of identifying inhibitors of gene silencing in mammalian cells
Mitchell Turker, Jon A. Oyer
Oregon Health & Science University
Patent number: 9,034,645
Issue Date: May 19, 2015


Translation-coupling systems
Wisconsin Alumni Research Foundation
Patent number: 9,034,641
Issue Date: May 19, 2015


Microfluidic hanging drop chip
Chia-Hsien Hsu, Chih-Chen Chen
National Tsing Hua University
Patent number: 9,034,636
Issue Date: May 19, 2015


Butanal production using engineered
Robert Doyle, Joshua Lensbouer, Anthony Vortherms
Syracuse University
Patent number: 9,034,616
Issue Date: May 19, 2015


Process for the preparation of (3R)-hydroxybutyl (3R)-hydroxybutyrate by enzymatic enantioselective reduction employing
Jeremy Robertson, Kieran Clarke, Richard Lewis Veech
Department of Health and Human Services
Patent number: 9,034,613
Issue Date: May 19, 2015


Reagents and methods for PCR
Lawrence J. Wangh, John Rice, Nicholas Rice, Yanwei Jia
Brandeis University
Patent number: 9,034,605
Issue Date: May 19, 2015


Methodology for verifying carbon storage in seawater
Anthony Michaels, Sergio Sanudo-Wilhelmy, Douglas Capone, James Moffett
University of Southern California
Patent number: 9,034,594
Issue Date: May 19, 2015


Three-dimensional, prevascularized, engineered tissue constructs, methods of making and methods of using the tissue constructs
, , ,
University of Alabama, Birmingham
Patent number: 9,034,571
Issue Date: May 19, 2015


Cell-adhesive, enzymatically crosslinked flavonoid hydrogels and methods for making same
Agency for Science, Technology and Research
Patent number: 9,034,364
Issue Date: May 19, 2015


Journal of Commercial Biotechnology This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Intellectual property: The driving force for growth and funding

Go to paper

ABSTRACT: For most 'bio-entrepreneurs' the science is the easy part -- leveraging that science to create a viable business becomes the real challenge. This paper provides an overview for utilising intellectual property to strengthen a business' attributes, thereby increasing the firm's likelihood of attracting funding and attaining its objectives...

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

  • Management
  • Policy
  • Finance
  • Law
  • Regulation
  • Bioethics

For more information, see the Journal of Commercial Biotechnology website

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below.

Susan Kling Finston

As a Non-NRI, I did not plan to launch a bio-pharmaceutical start-up company in India on my own. That would be a little crazy. Instead I took a leap of faith to co-found Amrita Therapeutics together with biotechnology pioneer Dr. Ananda M. Chakrabarty, an Indian-born scientist awarded the first-ever biotech patent following the U.S. Supreme Court decision in Diamond v. Chakrabarty (1980).

Ananda Chakrabarty is an articulate and passionate advocate for the importance of patent protection,  and gifted biotechnology pioneer. We first worked together in the lead-up to India’s re-adoption of product patent protection for pharmaceuticals during my tenure with the Pharmaceutical Research and Manufacturers of America (PhRMA) trade association. At that time, he already had experience with biotech start-ups in the United States, and began to see the potential opportunities for starting a new company in India:

Even before passage of the Third Patent Amendments in 2005, we began to talk about how wonderful it would be to-be-able-to establish a new biotech start-up company in India. We would benefit from full patent protection and do research on everything from soup to nuts. We would be able to bring entirely new, innovative bio-pharmaceutical therapies to market. This was the seed of Amrita Therapeutics.

Ultimately we agreed to organize the company in the state of Gujarat, due to the attractive commercial environment under long-time Chief Minister Narendra Modi, who had set up the Gujarat Biotechnology Venture Fund (GBVF) to attract innovative biotech start-ups. Following agreement on seed funding with Gujarat’s venture arm GVFL, Amrita Therapeutics had a soft-launch at Vibrant Gujarat in 2009 where I had the honor of meeting now Prime Minister Modi for a brief discussion of Amrita Therapeutics’ goal to bring new, innovative therapies and cures to meet the needs of patients in India and around the world. 

Gujarat was booming under the tenure of the BJP, and  generally it was a time when everything seemed possible in India even while the West staved off economic collapse. At that time we fully expected to be among the first of a large cohort of Biotech startups in India, also known as Micro-Small and Medium Enterprises (MSME), and this has not yet occurred. In fact, Amrita Therapeutics remains the only Indian biotech to have won the BIO Industry’s “Buzz of BIO” award.

Over the years I have offered observations as to how India could strengthen the environment for innovative biopharmaceutical development both at the State level and from the center relating to intellectual property protection, technology transfer, etc. These include specific policy recommendations in the recently published Innovation Blueprint Study commissioned by the Wadhwani Foundation. For example, fundraising for innovative product development in India remains highly challenging, due to the dearth of Angel Investor and VC culture for biopharma, where the Government would be well-advised to implement investment tax credits to promote investment by High-Net Worth Individuals. 

For now, though I would like to end on the positive note as to why we started Amrita Therapeutics in India and remain a Gujarati company to date. In late 2008 Ananda and I were able to reach agreement for modest seed funding from GVFL on the basis of what was then a highly novel research approach – only now six years on it may be the ‘flavor of the month.’  Similarly, despite the challenges of grant-in-aid programs administered by Delhi-based Government institutions, we continue to find receptivity for original thought and iconoclastic science akin to the early days of biotechnology in the United States. Simply put, while India lacks critical elements to become a growth center for innovative biotechnology, it does not lack for imagination.  This is enabling Amrita Therapeutics to bring new and better therapies to patients around the world that are “Made in India.”

 

About the author:
President of Finston Consulting LLC since 2005, Susan works with innovative biotechnology and other clients ranging from start-up to Fortune-100, providing support for legal, transactional, policy and “doing business” issues in the US and globally. Together with biotechnology pioneer Ananda Chakrabarty, she also is co-founder of Amrita Therapeutics Ltd., an emerging biopharmaceutical company based in India with peptide drugs in in vivo research. Previous experience includes 11 years in the U.S Foreign Service with overseas tours in London, Tel Aviv, and Manila and at the Department of State in Washington DC. For more information on latest presentations and publications please visit finstonconsulting.com.

DrugPatentWatch provides competitive intelligence on small-molecule drugs and the 90,000 global patents covering them

Click the patents below for more details, or visit DrugPatentWatch.com for more options.

CADUET (amlodipine besylate; atorvastatin calcium)
Pfizer
Patent number: 5,686,104
Expiration Date: May 11, 2015


LIPTRUZET (atorvastatin calcium; ezetimibe)
Merck Sharp Dohme
Patent number: 5,686,104
Expiration Date: May 11, 2015


LIPITOR (atorvastatin calcium)
Pfizer
Patent number: 5,686,104
Expiration Date: May 11, 2015


AFREZZA (insulin recombinant human)
Sanofi Aventis
Patent number: 8,394,414
Expiration Date: May 15, 2015


AFREZZA (insulin recombinant human)
Sanofi Aventis
Patent number: 6,071,497
Expiration Date: May 15, 2015


AFREZZA (insulin recombinant human)
Sanofi Aventis
Patent number: 6,428,771
Expiration Date: May 15, 2015


For more information try a free trial

DrugPatentWatch provides competitive intelligence on small-molecule drugs and the 90,000 global patents covering them

Click the patents below for more details, or visit DrugPatentWatch.com for more options.

CADUET (amlodipine besylate; atorvastatin calcium)
Pfizer
Patent number: 5,686,104
Expiration Date: May 11, 2015


LIPTRUZET (atorvastatin calcium; ezetimibe)
Merck Sharp Dohme
Patent number: 5,686,104
Expiration Date: May 11, 2015


LIPITOR (atorvastatin calcium)
Pfizer
Patent number: 5,686,104
Expiration Date: May 11, 2015


AFREZZA (insulin recombinant human)
Sanofi Aventis
Patent number: 8,394,414
Expiration Date: May 15, 2015


AFREZZA (insulin recombinant human)
Sanofi Aventis
Patent number: 6,071,497
Expiration Date: May 15, 2015


AFREZZA (insulin recombinant human)
Sanofi Aventis
Patent number: 6,428,771
Expiration Date: May 15, 2015


For more information try a free trial

TechTransferWatch is a search engine and alert service for licenseable technologies from academic labs, foundations, and government.

Click the patents below for more details, or visit TechTransferWatch.com for more options.

Conformationally restricted urea inhibitors of soluble epoxide hydrolase
University of California
Patent number: 9,029,550
Issue Date: May 12, 2015


Synthetic genes and genetic constructs
Commonwealth Scientific and Industrial Research Organisation
Patent number: 9,029,527
Issue Date: May 12, 2015


Signal activated RNA interference
Si-Ping Han, Robert D. Barish, William A. Goddard, III
California Institute of Technology
Patent number: 9,029,524
Issue Date: May 12, 2015


Anti-EGFR antibody and use thereof
Nobuyoshi Shimizu, Atsushi Takayanagi, Tetsuhiko Yoshida
Keio University
Patent number: 9,029,513
Issue Date: May 12, 2015


Method for native ligation of polypeptides
Oleg Melnyk, Reda Mhidia, Julien Dheur, Nathalie Ollivier, Oleg Melnyk, Reda Mhidia, Julien Dheur, Nathalie Ollivier
Institut Pasteur
Patent number: 9,029,503
Issue Date: May 12, 2015


Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
Mukesh K. Nyati, Theodore S. Lawrence
University of Michigan
Patent number: 9,029,502
Issue Date: May 12, 2015


Methods of treatment of skin ulcers
Robert Wilensky, Damir Hamamdzic, Harrilla Profka
University of Pennsylvania
Patent number: 9,029,383
Issue Date: May 12, 2015


Xenobiotic related induction of gene expression
Christopher Liddle, Bryan James Goodwin
University of Sydney
Patent number: 9,029,336
Issue Date: May 12, 2015


Cross-linked peptides and proteins, methods of making same, and uses thereof
Qing Lin, Avinash Muppidi
State University of New York System
Patent number: 9,029,332
Issue Date: May 12, 2015


Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands
Steven M. Jay, Linda G. Griffith, Richard T. Lee
Massachusetts Institute of Technology
Patent number: 9,029,328
Issue Date: May 12, 2015


Methods and compositions for enhanced differentiation from embryonic stem cells
Clark K. Colton, Daryl E. Powers, Jeffrey R. Millman
Massachusetts Institute of Technology
Patent number: 9,029,147
Issue Date: May 12, 2015


Mesenchymal stem cell conditioned medium
Sai Kiang Lim, Elias Lye
Agency for Science, Technology and Research
Patent number: 9,029,146
Issue Date: May 12, 2015


Chondrogenic progenitor cells, protocol for derivation of cells and uses thereof
Brendon Stewart Noble, David Matthew Pier
University of Edinburgh
Patent number: 9,029,145
Issue Date: May 12, 2015


Method of degrading TBP using a photosynthetic bacterial strain
Daniel Garcia, Cécile Berne
Commissariat a l’Energies Atomique et aux Energies Alternatives
Patent number: 9,029,127
Issue Date: May 12, 2015


Composition for the cultivation of sophisticated bacteria
Volkhard Kempf
Eberhard Karls University of Tübingen
Patent number: 9,029,119
Issue Date: May 12, 2015


Microfluidic vortex-assisted electroporation system and method
Harvard
Patent number: 9,029,109
Issue Date: May 12, 2015


Vitro evolution in microfluidic systems
Andrew David Griffiths, David Weitz, Darren Link, Keunho Ahn, Jerome Bibette
Harvard
Patent number: 9,029,083
Issue Date: May 12, 2015


Vaccine against
Roland Contreras, Kristof De Vusser, Silvia Revelli
Ghent University
Patent number: 9,028,844
Issue Date: May 12, 2015


Methods and compositions for poxvirus A35R protein
East Carolina University
Patent number: 9,028,837
Issue Date: May 12, 2015


Globo H and related anti-cancer vaccines with novel glycolipid adjuvants
Chi-Huey Wong, Chung-Yi Wu, Alice L. Yu, John Yu
Academia Sinica
Patent number: 9,028,836
Issue Date: May 12, 2015


Antibodies binding to adrenomedullin receptors and uses thereof as drugs
L’Houcine Ouafik, Kamel Mabrouk, Itidal Kaafarany, Pierre-Marie Martin
Aix-Marseille University
Patent number: 9,028,818
Issue Date: May 12, 2015


DrugPatentWatchdrugpatentwatch-pin has expanded its global coverage of pharmaceutical patents by adding coverage of Supplementary Protection Certificates.

DrugPatentWatch provides deep knowledge on pharmaceutical drugs and the 90,000 global patents covering them. Uses cases include:

Payers: Formulary and pharmacy & therapeutics (P&T)

Anticipate future budget requirements and proactively identify generic sources

Branded pharmaceutical manufacturers

Assess past successes of patent challengers and elucidate research paths of competitors

Specialty pharmaceuticals and generics

Identify market entry opportunities and inform portfolio management decisions

Buyers, wholesalers, and distributors

Predict branded drug patent expiration, identify generic suppliers, and prevent overstock of branded drugs

API manufacturers

Obtain formulation and manufacturing information; identify final formulators, repackagers, and relabellers

The addition of Supplementary Protection Certificates expands coverage of European markets, and helps identify drugs which have these patent extensions.

For more information see www.DrugPatentWatch.com or sign up for a free trial at www.DrugPatentWatch.com/trial.php

Drug Patent Expirations for May 2015

Tradename Applicant Generic Name Patent Number Patent Expiration
ACCUPRIL Pfizer Pharms quinapril hydrochloride 5,684,016*PED May 4, 2015
INTEGRILIN Schering eptifibatide 5,747,447 May 5, 2015
LIPTRUZET Merck Sharp Dohme atorvastatin calcium; ezetimibe 5,686,104*PED May 11, 2015
LIPITOR Pfizer atorvastatin calcium 5,686,104*PED May 11, 2015
CADUET Pfizer amlodipine besylate; atorvastatin calcium 5,686,104*PED May 11, 2015
AFREZZA Sanofi Aventis insulin recombinant human 6,071,497 May 15, 2015
AFREZZA Sanofi Aventis insulin recombinant human 6,428,771 May 15, 2015
AFREZZA Sanofi Aventis insulin recombinant human 8,394,414 May 15, 2015
RISPERDAL CONSTA Janssen Pharms risperidone 5,688,801*PED May 18, 2015
SANDOSTATIN LAR Novartis octreotide acetate 5,688,530*PED May 18, 2015
ZYVOX Pharmacia And Upjohn linezolid 5,688,792*PED May 18, 2015
ASMANEX TWISTHALER Merck Sharp Dohme mometasone furoate 5,687,710*PED May 18, 2015
MACUGEN Valeant Pharms Llc pegaptanib sodium 6,051,698 May 19, 2015
LIVALO Kowa Co pitavastatin calcium 5,753,675 May 19, 2015
OCTREOSCAN Mallinckrodt indium in-111 pentetreotide kit 5,753,627 May 19, 2015
NEXIUM 24HR Astrazeneca Lp esomeprazole magnesium 5,690,960*PED May 25, 2015
NEXIUM Astrazeneca Pharms esomeprazole magnesium 5,690,960*PED May 25, 2015
EGRIFTA Theratechnologies tesamorelin acetate 5,861,379 May 26, 2015
ABLAVAR Lantheus Medcl gadofosveset trisodium 8,017,105 May 26, 2015
EGRIFTA Theratechnologies tesamorelin acetate 6,020,311 May 26, 2015
ABLAVAR Lantheus Medcl gadofosveset trisodium 7,229,606 May 26, 2015
ABLAVAR Lantheus Medcl gadofosveset trisodium 7,060,250 May 26, 2015
NEXIUM IV Astrazeneca Pharms esomeprazole sodium 6,143,771 May 27, 2015
SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS Us Army perfluoropolymethylisopropyl ether; polytetrafluoroethylene 5,607,979 May 30, 2015
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Subscribers have access to valuable datasets, including:

  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison.
Contact Us with any questions.